Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
AssigneeTibotec Pharmaceuticals Ltd.
InventorsInge DIERYNCK, Sandra DE MEYER
Life of this patent
Estimating the term…
Abstract
The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.
Claims6
A method for evaluating the efficacy of a therapy regimen that includes a protease inhibitor against a mutant HIV, comprising:
- assessing whether said HIV comprises a mutation E428G in the gag gene, wherein the codon number of said E428G mutation corresponds to a wild type HIV IIIB/LAI reference sequence;
- based on said assessment, either withholding or applying said therapy regimen, wherein the presence of the mutation is correlated with decreased efficacy of the therapy regimen.
A method for evaluating viral drug susceptibility, comprising:
- collecting a sample from a patient infected with HIV;
- determining whether the sample comprises a HIV gag-pol having a mutation E428G in the gag gene, wherein the codon number of said E428G mutation corresponds to a wild type HIV IIIB/LAI reference sequence;
- based on said determination, assessing whether said HIV infection is characterized by decreased viral drug susceptibility, wherein the presence of the mutation E428G is correlated with decreased viral drug susceptibility.
Dependencies are inferred from the claim text.